Angelman syndrome (AS) is a neurodevelopmental disorder largely due to abnormal maternal expression of the UBE3A gene leading to the deletion of E6-associated protein. AS subjects have severe cognitive impairments for which there are no therapeutic interventions. Mouse models (knockouts of the maternal Ube3a gene: 'AS mice') of the disorder have substantial deficits in long-term potentiation (LTP) and learning. Here we report a clinically plausible pharmacological treatment that ameliorates both deficits. AS mice were injected ip twice daily for 5 days with vehicle or the ampakine CX929; drugs of this type enhance fast EPSCs by positively modulating AMPA receptors. Theta burst stimulation (TBS) produced a normal enhancement of field EPSPs in hippocampal slices prepared from vehicle-treated AS mice but LTP decreased steadily to baseline; however, LTP in slices from ampakine-treated AS mice stabilized at levels found in wild-type controls. TBS-induced actin polymerization within dendritic spines, an essential event for stabilizing LTP, was severely impaired in slices from vehicle-treated AS mice but not in those from ampakine-treated AS mice. Long-term memory scores in a fear conditioning paradigm were reduced by 50% in vehicle-treated AS mice but were comparable to values for littermate controls in the ampakine-treated AS mice. We propose that AS is associated with a profound defect in activity-driven spine cytoskeletal reorganization, resulting in a loss of the synaptic plasticity required for the encoding of long-term memory. Notably, the spine abnormality along with the LTP and learning impairments can be reduced by a minimally invasive drug treatment.
Introduction
Angelman syndrome (AS) is a rare (1 in~15,000 live births) neurogenetic disorder associated with cognitive impairment, motor dysfunction, and frequent co-diagnosis of autism spectrum disorder. Microcephaly, seizures, and severe speech impairments are also prominent components of the AS phenotype (Oliver et al., 2007) . AS most often arises from deletions in the 15q11-q13 region of the maternally inherited chromosome 15 (Williams et al., 1990) . One of the deleted genes, UBE3A, encodes the E6-associated protein (E6AP), which functions both as an E3 ligase in the ubiquitin proteasome pathway (Greer et al., 2010; Margolis et al., 2010; Scheffner et al., 1993) , and as a transcriptional co-activator for steroid hormone receptors (Nawaz et al., 1999) . As mutations in UBE3A alone result in AS, deletion of E6AP is generally considered to be a primary contributor to the disorder (Lalande and Calciano, 2007) .
A mouse model of AS has been developed by deletion of the maternal Ube3a gene; the mutant mice exhibit several features of the human disease, including abnormal dendritic spine morphology (Dindot et al., 2008) and learning deficits (Jiang et al., 1998; van Woerden et al., 2007) . Possibly related to these two features, the animals also have a marked impairment of long-term potentiation (LTP). It has been proposed that the LTP problems are due to abnormal phosphorylation of CaMKII (van Woerden et al., 2007) and/or a deficiency in the activity related cytoskeletal protein Arc, which may be a substrate for E6AP (Greer et al., 2010) . We recently hypothesized that the plasticity defects in several developmental disorders reflect a failure of activity-driven signaling pathways that lead to the reorganization of the spine cytoskeleton required for consolidation of LTP and memory (Baudry et al., 2011) . In agreement with this, we report here that the spine actin polymerization that occurs shortly after LTP induction, and is critical to LTP stabilization (Kramar et al., 2006; Lin et al., 2005; Lynch et al., 2008) , does not occur in AS mice. This result indicates that AS shares a specific spine dysfunction with rodent models of two other human conditions -low estrogen Neurobiology of Disease 47 (2012) 210-215 
